Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiae252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Shamik Majumdar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health…. Hauptthemen laut MEDLINE: Chemokine CXCL10, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, remains endemic worldwide. Circulating levels of the chemokine CXCL10 are strongly positively associated with poor outcome; however, its precise role in SARS-CoV-2 pathogenesis and its suitability as a therapeutic target have remained undefined. Here, we challenged mice genetically deficient in Cxcl10 with a mouse-adapted strain of SARS-CoV-2. Infected male, but not female, Cxcl10−/− mice displayed increased mortality compared to wild type controls. Histopathological damage, inflammatory gene induction, and virus load in the lungs of male mice were not broadly influenced by Cxcl10 deficiency. However, accumulation of B and T lymphocytes in the lung parenchyma of infected mice was reduced in the absence of Cxcl10. Thus, during acute SARS-CoV-2 infection, Cxcl10 regulates lymphocyte infiltration in lung and confers protection against mortality. Our preclinical model results do not support targeting CXCL10 therapeutically in severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
- Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, United States.
- Inflammation Biology Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
- SARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
- Mucosal Immunobiology Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
ORCID-Profile: Shamik Majumdar, Sergio M Pontejo, Philip M Murphy
Förderung
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- Division of Intramural Research
- National Institutes of Health
Zitieren
APA
Majumdar, S., Weaver, J. D., Pontejo, S. M., Minai, M., Lu, X., Gao, J. L., Holmes, G., Johnson, R., Zhang, H., Kelsall, B. L., Farber, J. M., Alves, D. A., & Murphy, P. M. (2025). Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae252
Vancouver
Majumdar S, Weaver JD, Pontejo SM, Minai M, Lu X, Gao JL, et al. Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiae252
BibTeX
@article{Majumdar2025,
author = {Majumdar, Shamik and Weaver, Joseph D and Pontejo, Sergio M and Minai, Mahnaz and Lu, Xinping and Gao, Ji-Liang and Holmes, Gibran and Johnson, Reed and Zhang, Hongwei and Kelsall, Brian L and Farber, Joshua M and Alves, Derron A and Murphy, Philip M},
title = {Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiae252}
}
EUVIMED